Trubion retains development and commercialization rights to treatment for NHL and CLL.
Laureate Pharma will produce Trubion Pharmaceuticals’ non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) drug candidate. TRU-016 targets CD37, an antigen present on B cells.
The company expects to file an IND for TRU-016 in the second half of 2007 after completing preclinical testing.
Trubion currently retains all development and commercialization rights for the TRU-016 program.
